How Rocket
Science Health
Delivers Impact

Neurological disease and psychiatric disorders are top contributors to the global burden of disease.

Neurological diseases and psychiatric disorders that affect the brain and other parts of the central nervous system (CNS) are highly prevalent and top contributors to the overall global burden of disease.^{1, 2, 4, 5} The WHO estimates that brain disorders affect nearly 1 billion people worldwide.⁶ Another estimated 455 million people suffer from mental illness.³

Successful treatment has been limited because of the difficulty in getting therapeutics to the CNS. 

Successful treatment of many neurological and psychiatric disorders has been limited in large part due to the challenging nature of delivering therapeutics to the brain and the rest of the CNS.⁵ Less than 2% of small molecules and nearly 0% of large molecule therapeutics approved by the FDA can successfully pass the blood-brain barrier (BBB) and blood-cerebrospinal fluid barriers (BCSFB) without complex and often invasive drug-delivery techniques⁵.

Intranasal drug delivery has seen limited success due to low delivery efficiency to the olfactory region.

Intranasal drug-delivery has been explored as a non-invasive method of direct-to-brain drug delivery to address the problem posed by the BBB and BCSFB, but has seen limited success due to low delivery efficiency to the olfactory region. ⁷ With current intranasal spray devices, few molecules reach the olfactory mucosa of the upper nasal cavity where they can circumvent the BBB and travel to their targets in the CNS. Rocket Science Health offers a superior solution to achieve efficacious nose-to-brain drug-delivery.